דילוג לתוכן הראשי
xMedica

NCT06628908ClinicalTrials.gov

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

A Phase 3, Randomized, Double-blind, Placebo- and Active-Controlled Study of the Efficacy and Safety of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy

מגייסמקבל משתתפים כעת, לפי רשומת המרשם.
יצירת קשר עם המחקר

בקצרה

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).

שלב 3דרושים 1,100 משתתפים76 אתריםמדינה אחת

קטגוריות

רשום במרשם אחד

מחקר יחיד יכול להיות רשום בכמה מרשמים. אנו מציגים אותו פעם אחת ומקשרים לכל רשומה שברשותנו.

מידע הניסוי מוצג כפי שפורסם על ידי המרשם, בשפת המקור שלו.

מתעניינים במחקר הזה?

התחברות או צרו חשבון כדי לרשום את התעניינותכם ולעקוב אחר המחקר הזה.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 7 days after the recorded start)First posted 2024-10-08; recorded start 2024-10-01
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 92 other studies in this databaseCounted from the lead sponsor named in the record (Vertex Pharmaceuticals Incorporated)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm15/15

    Active-comparator control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 76 sites

  • Data monitoring committee0/7

    Data monitoring committee not stated in the record

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study: 1,100 participants (target), run at 76 sites.

How this score is built
  • Enrolment30/40

    1,100 participants (target)

  • Site count22/25

    76 sites

  • Country count0/15

    Single country

  • Planned duration8/10

    Planned over about 32 months

  • Sponsor scale7/10

    Vertex Pharmaceuticals Incorporated has led 90 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

תקציר

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).

מצבים רפואיים

  • Diabetic Peripheral Neuropathic Pain

זכאות

זכאות
מיןהכול
גילאים18 Years80 Years
מתנדבים בריאיםלא

זכאות כפי שנכתבה במרשם

Key Inclusion Criteria: * Body weight greater than or equal to (≥) 45 kilogram (kg) * Body mass index (BMI) ≥18.0 to less than (\<) 40.0 kilogram per meter square (kg/m\^2) * Diagnosis of diabetes mellitus type 1 or type 2 by glycosylated hemoglobin A1c (HbA1c) ≤9% and the presence of bilateral pain in lower extremities due to DPN * Weekly average of daily NPRS score ≥4 and less than or equal to (≤) 9 with limited variation in the 7-day Baseline Period Key Exclusion Criteria: * More than 3 missing daily NPRS scores during the 7-day Baseline Period * Any sensory abnormality (excluding DPN) as pre-specified in the protocol Other protocol defined Inclusion/Exclusion criteria may apply.

זכאות במשפטים פשוטים

הקריטריונים של רשומה זו טרם פורקו למשפטים נפרדים. טקסט המרשם שלמעלה שלם והוא הגרסה המחייבת.

תכנון המחקר

תכנון המחקר
סוג המחקרהתערבותי
שלבשלב 3
הקצאהאקראי
מודל ההתערבותPARALLEL
מטרה ראשיתTREATMENT
הסתרהQUADRUPLE (4)
גיוסדרושים 1,100 משתתפים

נותן חסות ושותפים

  • Vertex Pharmaceuticals Incorporated נותן חסות

זרועות והתערבויות

  • Suzetrigine (SUZ)EXPERIMENTAL

    Participants will be randomized to receive SUZ.

  • PregabalinACTIVE_COMPARATOR

    Participants will be randomized to receive Pregabalin.

  • PlaceboPLACEBO_COMPARATOR

    Participants will be randomized to receive placebo matched to SUZ and Pregabalin.

התערבויות

  • תרופה Placebo (matched to Pregabalin)

    Placebo matched to Pregabalin for oral administration.

  • תרופה Placebo (matched to SUZ)

    Placebo matched to SUZ for oral administration.

  • תרופה Pregabalin

    Capsules for oral administration.

  • תרופה Suzetrigine

    Tablets for oral administration.

מדדי תוצאה

  1. מדד תוצאה ראשוני

    Change From Baseline in the Weekly Average of Daily Pain Intensity on the Numeric Pain Rating Scale (NPRS) at Week 12 Compared to Placebo

    מסגרת זמן From Baseline up to Week 12

  2. מדד תוצאה משני

    Change From Baseline in the Medical Outcomes Study 36-item Short-form Health Status (SF 36v2) Physical Component Summary (PCS) Score at Week 12 Compared to Placebo (pooled with data from Study VX24-548-111)

    מסגרת זמן From Baseline up to Week 12

  3. מדד תוצאה משני

    Change From Baseline in the Weekly Average of Daily Pain Intensity on the NPRS at Week 12 Compared to Pregabalin

    מסגרת זמן From Baseline up to Week 12

תאריכים

תאריכים
תאריך התחלה1 באוקטובר 2024 (בפועל)
סיום ראשוני31 במאי 2027 (משוער)
סיום31 במאי 2027 (משוער)
פורסם לראשונה8 באוקטובר 2024 (בפועל)
עודכן לאחרונה15 ביוני 2026
התוצאות פורסמולא צוין ברשומת המרשם
המצב אומת לאחרונהיוני 2026

בפועל פירושו שהאירוע התרחש. משוער פירושו שנותן החסות צופה אותו. שתי המשמעויות שונות זו מזו.

מיקומים

59 אתרים מגייסים

United States

United States
מתקןעירמדינה או אזורמצב
Albany Medical CollegeAlbanyNew Yorkהושלם
Velocity Clinical Research - AlbuquerqueAlbuquerqueNew Mexicoמגייס
Synexus Clinical Research- AndersonAndersonSouth Carolinaהושלם
Pinnacle Research Group, LLCAnnistonAlabamaמגייס
Velocity Clinical Research - Baton RougeBaton RougeLouisianaמגייס
Velocity Clinical Research - ClevelandBeachwoodOhioמגייס
Northwest Clinical Research Center (NWCRC)BellevueWashingtonמגייס
Synexus Clinical Research - BirminghamBirminghamAlabamaהושלם
Mass General Brigham - Brigham and Women's Hospital - Main CampusBostonMassachusettsמגייס
Swift Clinical OpCo, IncBrooklynNew Yorkמגייס
Clinical Trials of South Carolina - Berkeley - CharlestonCharlestonSouth Carolinaמגייס
M3 Wake Research - CharlestonCharlestonSouth Carolinaמגייס
Feinberg School of Medicine - AnesthesiologyChicagoIllinoisמגייס
Synexus Clinical Research - CincinnatiCincinnatiOhioהושלם
Tandem Clinical Research- CovingtonCovingtonLouisianaמגייס
Synexus Clinical Research - Dallas (DFW) (DRS)DallasTexasהושלם
Zenos Clinical ResearchDallasTexasמגייס
AMR Daphne, ALDaphneAlabamaהושלם
META Medical Research InstituteDaytonOhioמגייס
Accel Research - DelandDeLandFloridaמגייס
Accel Research - DecaturDecaturGeorgiaמגייס
AMR-MiamiDoralFloridaמגייס
Velocity Clinical Research - ProvidenceEast GreenwichRhode Islandמגייס
Velocity Clinical Research - SyracuseEast SyracuseNew Yorkמגייס
Velocity Clinical Research - DenverEnglewoodColoradoמגייס
Synexus Clinical Research - EvansvilleEvansvilleIndianaהושלם
Healthcare Research Network - Flossmoor ILFlossmoorIllinoisמגייס
AMR Fort Myers (The Clinical Study Center)Fort MyersFloridaמגייס
Neuro-Pain Medical CenterFresnoCaliforniaמגייס
Velocity Clinical Research - Grants PassGrants PassOregonהושלם
Velocity Clinical Research - Hallandale BeachHallandaleFloridaמגייס
Healthcare Research Network - Hazelwood MOHazelwoodMissouriמגייס
CNS Healthcare - JacksonvilleJacksonvilleFloridaמגייס
AMR Kansas CityKansas CityMissouriמגייס
Accel Research - St. Petersburg-LargoLargoFloridaמגייס
Synexus Clinical Research - Las VegasLas VegasNevadaהושלם
AMR LexingtonLexingtonKentuckyמגייס
Long Beach Research InstituteLong BeachCaliforniaמגייס
Angel City Research, IncLos AngelesCaliforniaמגייס
Accel Research - MaitlandMaitlandFloridaהושלם
HRI - Hassman Research InstituteMarltonNew Jerseyהושלם
Velocity Clinical Research - MedfordMedfordOregonמגייס
Suburban Research Associates - MediaMediaPennsylvaniaמגייס
Velocity Clinical Research - BoiseMeridianIdahoמגייס
Suncoast Research Associates - MiamiMiamiFloridaמגייס
3Sync Research - Miami LakesMiami LakesFloridaמגייס
West Clinical ResearchMorehead CityNorth Carolinaמגייס
AMR Nashville, TNNashvilleTennesseeהושלם
Suncoast Clinical Research - New Port RicheyNew Port RicheyFloridaמגייס
Columbia Presbyterian - The Neurological Institute of New YorkNew YorkNew Yorkמגייס

26 אתרים נוספים מצוינים ברשומת המרשם.

מסמכי המחקר

לא צורפו מסמכים ברשומת מרשם זו.

שינויים לאורך זמן

לא נרשמו שינויים מאז שקלטנו רשומה זו לראשונה.

שינוי נרשם בכל פעם שנותן החסות מעדכן את רשומת המרשם. מצב, תאריכים, גיוס ואתרים מופיעים כאן ככל שהם משתנים.